Medline (PubMed) conducted a structured scoping review of published literature to identify information about the use of PLAs and IPL in Canada and around the world. The search terms included the following terms: „product rating agreement,“ „managed registration agreement,“ „risk-sharing agreement,“ „performance-based contract,“ „patient access scheme“ and „evidence development coverage.“ Similar terms have been used to search for grey literature in search of relevant websites, presentations and reports. Quotes that are relevant to the understanding of the PLA and IPLA types, their attributes and their use in Canada and around the world, have been identified by the title/abstract verification and selected for full review of the text. The results of literary criticism were used to develop a short reading for respondents. This paper would summarize the types and characteristics of PTPAs and IPAs, as well as key issues related to their development and use in Canada/internationally. The results of literary research were also used to provide information on two qualitative surveys: a 16-question survey for current payers, former payers/consultants and managers of drug control plans, and a five-question survey for representatives of the pharmaceutical industry (i.e. Chief Executive Officers [CEOs] and Vice-Presidents of Public Affairs (VPs) (Additional Materials). Two surveys were conducted to allow flexibility in the duration and concentration of the survey and to increase the ability to interact with different LOs. In an effort to increase the power of collective bargaining and to make available the benefits of ALP negotiations across Canada, the provinces have taken important steps to collaborate on the PLA negotiations through the Pan-Canadian Procurement Alliance. Cooperation is essential to justice for results in Canada, considering that Ontario`s public drug budget ($4.48 billion) is in line with Prince Edward Island`s total gross domestic product ($5.01 billion) (CIHI 2012); Statistics Canada 2011). To make cooperation a common and sustainable practice requires new resources to coordinate actors and maintain commitment to common decisions that often lead to significant local political pressure.
However, while a new global paradigm of confidential drug pricing has undermined the value of price regulation through international price comparisons, some federal support for cooperation in the PLA negotiations could be achieved through a modernization of the roles and regulations of the PMPRB or by redeployment of part of its $11.8 million budget (PMPRB 2012). Canadian Institute for Health Information (CIHI). Prescribed drug spending in Canada, 2013: the focus on public drug programs; 2013. Available from: secure.cihi.ca/free_products/Prescribed%20Drug%20Spending%20in 20Canada_2014_EN.pdf. Call on March 11, 2016. Unlike PCPA, which publishes information on the products analyzed and provides guidelines for the PLA process, there is currently no public information indicating the dissemination of private LDCs in Canada.
Comments are closed.